Peer-Reviewed Publications:
Wilson, C.D., Zheng, F., and Fantegrossi, W.E. (2022). Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in mice. Psychopharmacology (Berl.), 239 (10), 3237-3248. https://doi.org/10.1007/s00213-022-06205-6
Wilson, C. D., Hiranita, T., and Fantegrossi, W. E. (2022). Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal. Drug and alcohol dependence, 236, 109468. https://doi.org/10.1016/j.drugalcdep.2022.109468
Griffin, B.A., Caperton, C.O., Russell, L.N., Cabanlong, C.V., Wilson, C.D., Urquhart, K.R., Martin, B.S., Zita, M.D., Patton, A.L., Alund, A.W., Owens, S.M., Fantegrossi, W.E., Moran, J.H., and Brents, L.K. (2019). In utero exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. J. Pharmacol. Exp. Ther., 370(1), 9-17. https://doi.org/10.1124/jpet.118.254219
Wilson, C.D., Tai, S., Ewing, L., Crane, J., Lockhart, T., Yarbrough, A.L., Fujiwara, R., Radominska-Pandya, A., and Fantegrossi, W.E. (2019). Convulsant effects of abused synthetic cannabinoids JWH-018 and 5F-AB-PINACA are mediated by agonist actions at CB1 receptors in mice. J. Pharmacol. Exp. Ther., 368(2), 146-156. https://doi.org/10.1124/jpet.118.251157
Tai, S., Vasiljevik, T., Sherwood, A.M., Eddington, S., Wilson, C.D., Prisinzano, T.E., and Fantegrossi, W.E. (2018). Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist/ CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend., 192, 285-293. https://doi.org/10.1016/j.drugalcdep.2018.08.011
Hutchison, R.D., Ford, B.M., Franks, L.N., Wilson, C.D., Yarbrough, A.L., Fujiwara, R., Su, M.K., Fernandez, D., James, L.P., Moran, J.H., Patton, A.L., Fantegrossi, W.E., Radmoniska-Pandya, A., and Prather, P.L. (2018). Atypical pharmacodynamic properties and metabolic profile of the abused synthetic cannabinoid AB-PINACA: potential contribution to pronounced adverse effects relative to ∆9-THC. Front. Pharmacol., 9, 1084. https://doi.org/10.3389/fphar.2018.01084
Crowe, M.S., Wilson, C.D., Leishman, E., Prather, P.L., Bradshaw, H.B., Banks, M.L., and Kinsey, S.G. (2017). The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. Br. J. Pharmacol., 174(23), 4523-4539. https://doi.org/10.1111/bph.14055
Ford, B.M., Franks, L.N., Tai, S., Fantegrossi, W.E., Stahl, E.L., Berquist, M.D., Cabanlong, C.V., Wilson, C.D., Penthala, N.R., Crooks, P.A., and Prather, P.L. (2017). Characterization of structurally novel G protein biased CB1 agonists: implications for drug development. Pharmacol. Res., 125(Pt B), 161-177. https://doi.org/10.1016/j.phrs.2017.08.008
Review:
Fantegrossi, W.E., Wilson, C.D., and Berquist, M.D. (2018). Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab. Rev., 50(1), 65-73. https://doi.org/10.1080/03602532.2018.1428343